Chronic myeloid leukemia within a year of kidney transplant with elevated alkaline phosphatase correlated with imatinib therapy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The incidence of certain malignancies is significantly higher after organ transplant. However, there are rare reports of chronic myeloid leukemia in the posttransplant setting. The average reported interval between a transplant and the diagnosis of chronic myeloid leukemia is 44 months (range, 10-96 mo). We report 2 patients with chronic myeloid leukemia within 1 year of a kidney transplant, which is significantly shorter than those previously reported. Both patients were receiving mycophenolate mofetil and tacrolimus for immunosuppression. They were treated with imatinib for chronic myeloid leukemia, and both patients demonstrated an isolated elevation of serum alkaline phosphatase that was directly correlated with imatinib. Despite a potential interaction between the 2 drugs, blood levels of tacrolimus and imatinib were not elevated during the course of treatment. Isolated elevation of alkaline phosphatase in this particular setting has not been reported previously.

Original languageEnglish
Pages (from-to)336-339
Number of pages4
JournalExperimental and Clinical Transplantation
Volume9
Issue number5
StatePublished - Oct 2011

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Alkaline Phosphatase
Transplants
Kidney
Tacrolimus
Mycophenolic Acid
Therapeutics
Immunosuppression
Imatinib Mesylate
Incidence
Serum
Pharmaceutical Preparations
Neoplasms

Keywords

  • CML
  • Gleevec
  • Imatinib
  • Immunosuppression
  • Renal transplant

ASJC Scopus subject areas

  • Transplantation

Cite this

@article{f550aa371ef84f5b9cf579f35c4f1b72,
title = "Chronic myeloid leukemia within a year of kidney transplant with elevated alkaline phosphatase correlated with imatinib therapy",
abstract = "The incidence of certain malignancies is significantly higher after organ transplant. However, there are rare reports of chronic myeloid leukemia in the posttransplant setting. The average reported interval between a transplant and the diagnosis of chronic myeloid leukemia is 44 months (range, 10-96 mo). We report 2 patients with chronic myeloid leukemia within 1 year of a kidney transplant, which is significantly shorter than those previously reported. Both patients were receiving mycophenolate mofetil and tacrolimus for immunosuppression. They were treated with imatinib for chronic myeloid leukemia, and both patients demonstrated an isolated elevation of serum alkaline phosphatase that was directly correlated with imatinib. Despite a potential interaction between the 2 drugs, blood levels of tacrolimus and imatinib were not elevated during the course of treatment. Isolated elevation of alkaline phosphatase in this particular setting has not been reported previously.",
keywords = "CML, Gleevec, Imatinib, Immunosuppression, Renal transplant",
author = "Hamid Sayar and Asif Sharfuddin and Tim Taber and Rakesh Mehta",
year = "2011",
month = "10",
language = "English",
volume = "9",
pages = "336--339",
journal = "Experimental and Clinical Transplantation",
issn = "1304-0855",
publisher = "Baskent University",
number = "5",

}

TY - JOUR

T1 - Chronic myeloid leukemia within a year of kidney transplant with elevated alkaline phosphatase correlated with imatinib therapy

AU - Sayar, Hamid

AU - Sharfuddin, Asif

AU - Taber, Tim

AU - Mehta, Rakesh

PY - 2011/10

Y1 - 2011/10

N2 - The incidence of certain malignancies is significantly higher after organ transplant. However, there are rare reports of chronic myeloid leukemia in the posttransplant setting. The average reported interval between a transplant and the diagnosis of chronic myeloid leukemia is 44 months (range, 10-96 mo). We report 2 patients with chronic myeloid leukemia within 1 year of a kidney transplant, which is significantly shorter than those previously reported. Both patients were receiving mycophenolate mofetil and tacrolimus for immunosuppression. They were treated with imatinib for chronic myeloid leukemia, and both patients demonstrated an isolated elevation of serum alkaline phosphatase that was directly correlated with imatinib. Despite a potential interaction between the 2 drugs, blood levels of tacrolimus and imatinib were not elevated during the course of treatment. Isolated elevation of alkaline phosphatase in this particular setting has not been reported previously.

AB - The incidence of certain malignancies is significantly higher after organ transplant. However, there are rare reports of chronic myeloid leukemia in the posttransplant setting. The average reported interval between a transplant and the diagnosis of chronic myeloid leukemia is 44 months (range, 10-96 mo). We report 2 patients with chronic myeloid leukemia within 1 year of a kidney transplant, which is significantly shorter than those previously reported. Both patients were receiving mycophenolate mofetil and tacrolimus for immunosuppression. They were treated with imatinib for chronic myeloid leukemia, and both patients demonstrated an isolated elevation of serum alkaline phosphatase that was directly correlated with imatinib. Despite a potential interaction between the 2 drugs, blood levels of tacrolimus and imatinib were not elevated during the course of treatment. Isolated elevation of alkaline phosphatase in this particular setting has not been reported previously.

KW - CML

KW - Gleevec

KW - Imatinib

KW - Immunosuppression

KW - Renal transplant

UR - http://www.scopus.com/inward/record.url?scp=80053962877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053962877&partnerID=8YFLogxK

M3 - Article

C2 - 21967261

AN - SCOPUS:80053962877

VL - 9

SP - 336

EP - 339

JO - Experimental and Clinical Transplantation

JF - Experimental and Clinical Transplantation

SN - 1304-0855

IS - 5

ER -